摘要
Dear Editor,Nowadays,two autologous CAR19-T drugs,Tisagenlecleucel(Kymriah^(TM))and axicabtagene ciloleucel(Yescarta^(TM)),have been approved for the treatment of B cell leukemia and lymphoma and achieved unprecedented successes.However,about 10-20%of B-ALL patients receiving CAR19-T drugs didn't achieve complete remission(CR),while 30~50%of patients achieved CR would relapse mainly within 1 year.Moreover,the high CR rate of CAR19-T therapy for B-ALL can't be recaptured in other B-NHLs,'such as Burkitt's lymphoma(BL).Therefore,there is an urgent need to improve the therapeutic efficacy of CAR19-T cells.3.
基金
This work was supported by the National Key Research and Development Program of China(2016YFC0905100)
the National Natural Science Foundation of China(81770200)
the Major Scientifc and Technological Projects for Collaborative Prevention and Control of Birth Defects in Hunan Province(20195K1010).
